CA
TRDA icon

CHI Advisors’s Entrada Therapeutics TRDA Stock Holding History

CHI Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-56,374
Closed -$817K – 28
2023
Q1 		$817K Buy
+56,374
New +$753K 0.22% 22
2022
Q3 		– Sell
-163,496
Closed -$1.99M – 27
2022
Q2 		$1.99M Buy
+163,496
New +$1.24M 0.76% 22

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

CHI Advisors's TRDA Position: Q2 2023 in Review

CHI Advisors sold out of Entrada Therapeutics (TRDA) in Q2 2023, closing a stake of 56,374 shares — an estimated $817K sold.

CHI Advisors first reported a position in TRDA in Q2 2022 and held it in 2 quarters. The position peaked at $1.99M in Q2 2022. 56 funds tracked by Wall St. Rank hold TRDA as of Q2 2023.

  • CHI Advisors reported no remaining Entrada Therapeutics position as of Q2 2023 after selling out during the quarter.
  • CHI Advisors sold 56,374 Entrada Therapeutics shares in Q2 2023, an estimated $817K.
  • CHI Advisors first reported a position in Entrada Therapeutics in Q2 2022 and held it in 2 quarters.
  • CHI Advisors's Entrada Therapeutics position peaked at $1.99M in Q2 2022.
  • 56 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2023.

Based on CHI Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.